AGP Picks
View all

Nabi-HB market growth tied to rising hepatitis B risk and aging populations

Nov. 9, 2026
Nabi-HB market growth tied to rising hepatitis B risk and aging populations
By AI, Created 00:45 UTC, Nov 09, 2026, AGP -

The Nabi-HB market is expected to keep expanding as hepatitis B prevention efforts intensify, chronic disease rates stay elevated and older populations grow. North America held the largest market share in 2025, according to The Business Research Company.

Why it matters: - Nabi-HB is a post-exposure hepatitis B immune globulin used when immediate passive immunity is needed. - Demand tracks with hepatitis B exposure risk, chronic disease burden and the needs of older adults with weaker immune systems. - The market is also being shaped by broader prevention efforts, which can increase use of emergency immunoprophylaxis.

What happened: - The Business Research Company published an analysis of the Nabi-HB market on Nov. 9, 2026. - The report says the Nabi-HB market is gaining momentum as efforts to combat hepatitis B infection intensify globally. - North America held the largest share of the Nabi-HB market in 2025. - The analysis also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Nabi-HB is a human hepatitis B immune globulin designed for post-exposure prophylaxis against hepatitis B virus infection. - The product is used after needlestick injuries, surgeries and other exposures to HBV. - Nabi-HB provides antibodies directly and offers temporary protection until the body’s own immune defenses become active. - Historical market growth has been supported by the global prevalence of hepatitis B, the role of immune globulins in prevention and the expansion of vaccination programs. - Plasma fractionation technology advances and higher occupational exposure risks have also supported demand. - Future growth is expected to come from intensified hepatitis prevention efforts, stronger attention to high-risk groups, rising demand for emergency immunoprophylaxis, plasma purification advances and public health preparedness initiatives. - Key trends include greater reliance on passive immunization therapies, more use of hepatitis B immune globulin for post-exposure prophylaxis, stronger infection control strategies, growth in plasma-derived treatments and demand for rapid immune protection. - Rising hepatitis B prevalence remains a core driver because the infection can lead to chronic liver disease and liver cancer. - Lower vaccination coverage, unprotected sexual activity, needle sharing among drug users and limited healthcare access in vulnerable regions are adding to hepatitis B cases. - The US Centers for Disease Control and Prevention reported in 2023 that people ages 40 to 59 accounted for 48% of acute hepatitis B cases. - Chronic disease growth is also lifting demand because patients with ongoing conditions need more preventive care. - The CDC reported in April 2025 that 76.4% of US adults had at least one chronic condition in 2023. - An aging population is another demand factor because older adults are more vulnerable to infection and complications. - The UK Parliament's House of Commons Library reported that 12.7 million people in the UK were 65 or older in 2022, equal to 19% of the population, and projected that figure to reach 22.1 million by 2072.

Between the lines: - The market is being driven by prevention, not treatment alone, which gives passive immunity products a durable role in health systems. - The report points to a mix of public health, demographic and clinical pressures that can sustain demand even if hepatitis B vaccination rates improve. - North America's lead suggests established healthcare infrastructure and screening practices may support stronger uptake of prophylaxis products.

What's next: - The market is expected to expand as hepatitis prevention efforts intensify and emergency protection needs remain elevated. - Ongoing improvements in plasma purification and public health readiness are likely to support future growth. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - Contact details for expert inquiries were included in the release, along with links to the company’s social channels.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Middle East News Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East News Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.